drugset
drugset / Trial / NCT04236635

Histopathology Following CCH Injection

NCT04236635 ↗

Phase 2 Completed 10 enrolled Endo USA Inc., a Keenova Therapeutics Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

To evaluate the histopathology of subcutaneous tissue isolated after single or multiple Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female participants undergoing abdominoplasty.

Timeline

Start
2019-12-20
Primary completion
2020-09-23
Completion
2020-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.0653 mg Subcutaneous
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.07 mg Subcutaneous

Indications

No indication recorded.